Cancer Immunotherapy Harnessing Innate and Adaptive Immune Effector Cells and PD-1 Immune Checkpoint Inhibitors
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 8736
Special Issue Editor
Interests: γδ T cell; NK cell; cancer immunotherapy; PD-1; IL-18; adoptive transfer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The idea of harnessing a patient’s immune system to combat cancer originated in the nineteenth century. Wilhelm Busch and Friedrich Fehleisen first described the association between the spontaneous regression of tumors and the development of erysipelas, induced by Streptococcus pyogenes. Subsequently, William B. Coley treated sarcoma patients with cultured streptococci, observing the shrinkage in malignant tumors. This suggested, of course, that the immune system, stimulated by infections, might be responsible for tumor regression. Based on these initial observations on the possible link between infections and tumor rejection, many researchers began to explore the development of immunotherapy of cancer. Most of the attempts were, however, unsuccessful until recently, owing to the lack of reproducibility, coupled with the complexity of the immune system.
The development of immune checkpoint inhibitors—anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) mAb, anti-programmed death-1 (PD-1) mAb and anti-PD-1 ligand 1 (PD-L1) mAb, and chimeric antigen-receptor (CAR)-T cells—suddenly revolutionized cancer treatments in 2010s. The immune checkpoint molecules are physiologically negative regulators of T-cell activation and maintain self-tolerance. The rationale of immune checkpoint therapy is to target the host immune system, in particular, T cells. However, this does not impact malignant tumors per se, as in conventional treatments like chemotherapy and radiotherapy. CAR-T cells-based therapy is successful for the treatment of B lymphoma. While the introduction of the immune checkpoint inhibitors and CAR-T cells has opened a new era for cancer therapy, the efficacy of the techniques is not yet satisfactory. It is thus imperative to further develop novel cancer immunotherapies, including both PD-1 immune checkpoint combination therapy and the adaptive transfer of immune effector cells, such as genetically- or chemically-modified CAR-T cells, γδ T cells, and NK cells. In order to improve the efficacy of such novel cancer treatments, it is essential to delineate the precise mechanism underlying the effect of modified immune effector cells on tumor cells. Within this Special Issue of Cells, we will highlight the molecular mechanisms and future directions of PD-1 immune checkpoint inhibitor combination therapy and immune effector cells-based immunotherapies. To this end, we invite the submission of original articles and reviews in this exciting field of research.
Prof. Dr. Yoshimasa Tanaka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PD-1 immune checkpoint
- CAR-T cells
- γδ T cells
- NK cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
